Kaylan Weese, M.D.
NPI 1134449366 · Dermatology Physician · Roseburg, OR
Provider details
- NPI number
- 1134449366
- Entity type
- Individual
- Primary specialty
- Dermatology PhysicianAllopathic & Osteopathic Physicians
- Credential
- M.D.
- Sex
- Female
- Sole proprietor
- No
- License
- PG163762 (OR)
Specialties & taxonomies
Allopathic & Osteopathic Physicians
Profile Score
A profile completeness & documented-activity index — NOT a quality, outcomes, or patient-satisfaction rating.
- Registry tenure25% of score
16 yrs in NPPES registry
- Profile completeness25% of score
100% of core fields populated
- Practice footprint15% of score
1 documented practice location
- Medicare service volume (vs. specialty peers)25% of score
4,487 Medicare services, 2024 (ranked within specialty)
- Open Payments transparency10% of score
Has Open Payments disclosures (2024)
Medicare volume is ranked against active providers in the same specialty. Signals a provider has no public data for (e.g. Medicare claims) are left out of the score entirely — never counted as zero — so providers without that data are not penalized. See the full formula and weights in our .
What this provider does (Medicare)
Based on Medicare fee-for-service claims, 2024; not all care is captured.
| Service (HCPCS) | Medicare services | Typical Medicare-allowed (2024) |
|---|---|---|
| Pathology Examination of Tissue Using a Microscope, Intermediate Complexity88305 | 1,026 | $36 |
| Established Patient Office Or Other Outpatient Visit With Low Level OD Decision Making, If Using Time, 20 Minutes Or More99213 | 990 | $91 |
| Destruction of Precancer Skin Growth, 2-14 Growths17003 | 797 | $7 |
| Destruction of Precancer Skin Growth, 1 Growth17000 | 372 | $54 |
| Biopsy of Related Skin Growth, First Growth11102 | 325 | $90 |
| Destruction of Skin Growth, 1-14 Growths17110 | 282 | $113 |
Transparency — industry payments
Based on CMS Open Payments, 2024; not all care is captured.
$538 across 53 records (Open Payments 2024)
Open Payments discloses payments and transfers of value (meals, travel, consulting, research, royalties) from drug and device makers to providers. This is a transparency signal, not a verdict — such payments are legal and common, and their presence is neither an endorsement nor a criticism. Source: CMS Open Payments, program year 2024.
Practice location
Mailing address
Registry dates
- Enumerated
- 2010-06-10
- Last updated
- 2014-04-22
Source: CMS NPPES Data Dissemination (June 2026). NPI Central is not affiliated with CMS. Data is provided as-is from the public registry.